Skip to content
Oncology News Central Peer-Spectives cover art

All episodes

Oncology News Central Peer-Spectives, 100 episodes.

#
Title
1

How Are Oncologists Managing Amivantamab Plus Lazertinib in EGFR- Mutant NSCLC?

2

Who Still Needs Monotherapy in EGFR- Mutant NSCLC

3

Is It Time for a New Type of Cancer Physician?

4

What the “Tsunami” of Cancer Survivors Means for Oncologists

5

“Sobering” Takeaway From ASCO 2026: Concerns About Clinical Trial Participation

6

“A Lot More Asymptomatic Cancer Out There”: Major MCED Trial Hints at Complicated Future

7

“The Ever-Shifting and Chaotic” State of CLL Care: What New Data Mean for Practice

8

How “Drastically Better” Treatments for Some Colorectal Cancers Are Changing Care

9

“Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care

10

New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target”

11

Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic

12

Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care

13

Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC

14

“Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions

15

Second-Line Options in EGFR-Mutated NSCLC: What’s the Right Sequence?

16

“Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC

17

As Terminal Patients Live Longer, How Can Oncologists Help Them Cope With Uncertainty?

18

Should Patients With Cancer Receive mRNA Vaccines Alongside Immunotherapy?

19

Big News From ESMO 2025 Changes Practice in Bladder Cancer

20

Big Changes in AML Care as Targeted Therapy Options Expand

21

Artificial Sweetener May Impair Cancer Immunotherapy, Raising Broader Questions

22

“Massive Advance” Changes the Chessboard in EGFR-Mutated Metastatic NSCLC

23

Are Oral SERDs About to Transform Breast Cancer Care?

24

Game-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer Care

25

Practice-Changing Data in Colorectal Cancer Lead to Broader Questions in Oncology

26

Oncologist Faculty Burnout Caused by “Unrealistic” Expectations, Says ASCO CEO

27

After Years of Inactivity, “Dizzying” Changes Hit Bladder Cancer Care

28

Practice Changing or “Practice Confounding”? Pivotal Breast Cancer Data Raise Big Questions

29

NCCN CEO Discusses Guideline Updates, Other Key Initiatives

30

Former National Cancer Institute Director Discusses the Future of Cancer Care

31

Game-Changing Blood Cancer News at ASCO 2025: Rusfertide Shows Strong Benefit in Polycythemia Vera

32

Getting Americans to Support Cancer Research May Take a New Message, Oncology Leader Says

33

“Important Milestone”: Perioperative Durvalumab Improves Event-Free Survival in Gastric Cancer

34

What Does the Biggest News in Breast Cancer From ASCO 2025 Mean for Practice Right Now?

35

Practice-Changing “Inflection Point” Coming in ESR1-Positive Breast Cancer Care?

36

When ESR1 Mutations Arise in Breast Cancer Patients With PIK3CA Mutations: What Next?

37

How “Remarkable Change” in EGFR-Mutated NSCLC Care Is Making a Difference for Patients

38

Oncologists Urged to Discuss Fertility With Patients, as ASCO Updates Guidelines

39

“Second-Line ER-Positive Breast Cancer Has Just Become Very Complicated”

40

Will Generational Divide Among Oncologists Affect How AI Changes Cancer Care?

41

“Time to Move On”: How Targeted Therapies Are Transforming AML Care

42

ASCO President Speaks Out on “Huge Problem” of Oncologist Burnout

43

Oncologists Overtreat Patients at End of Life

44

FDA Approvals Change Practice for Metastatic Breast Cancer With PIK3CA Mutations

45

To Help Oncologists’ Burnout, Should Primary Care Take on More Burden?

46

Choosing Between an “Old Friend” and New Ones in EGFR-Mutated Metastatic NSCLC

47

Privatization of Cancer Clinical Research Raises Concerns for Practice

48

What 3 Big Trials Mean for Breast Cancer Practice

49

“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer

50

”Where Do We Go From Here?” Targeted Therapies Lead to Challenging Choices in Breast Cancer

51

After Practice Change in Unresectable Stage III NSCLC, Questions Remain

52

What ”Incredibly Dramatic” Data on Osimertinib in NSCLC Mean for Practice

53

“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates

54

Oncology Must Do More for Long-Term Cancer Survivors, Expert Says

55

“A Good, Peaceful Death” From Cancer: Oncologists Must Be Part of “National Dialogue”

56

FDA Approvals in Relapsed/Refractory CLL Set up ”Difficult Choice”

57

Oncologists Struggling With Cancer Deaths Among Millennial Patients

58

Top Lung Cancer Data From ASCO 2024 Should Change Practice “Immediately,” Experts Agree

59

What Were the Biggest Data at ASCO 2024 in Kidney Cancer?

60

What New “Elephant in the Room” Means for Bladder Cancer Care

61

Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice

62

”We’re Past the Inflection Point,” as ”Massive Change” Hits Breast Cancer Care

63

To Get Better Cancer Drugs Faster, Is It Time for an “International FDA”?

64

”Very Important” Myeloma Data: ASCO Highlights, Smoldering Challenges, and More

65

Durvalumab’s Benefit in SCLC ”Beyond What We Might Have Expected”

66

New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers ”Fantastic” Potential, Expert Says

67

Should All Breast Cancer Patients Get T-DXd? ”Results of DESTINY-Breast06 Do Suggest That”

68

Oncologist Shortage “Has Gotten to the Crisis Level”

69

“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use

70

“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care

71

Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer

72

FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming”

73

From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care

74

FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression

75

Controversies, Difficult Questions Arise in NSCLC Amid New Data

76

What FDA Approval of Belzutifan Means for Kidney Cancer Care

77

Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer

78

Which FDA Approvals, Other Advances Changed ER-Positive Breast Cancer Care in 2023?

79

“New Disruptor” in Prostate Cancer: PSMA PET and Other Treatment Advances

80

Practice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Strong Benefit

81

ER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2023

82

Inside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: Lessons Learned

83

First-Line Osimertinib Plus Chemo in NSCLC: How to Weigh Toxicity vs. Efficacy

84

What Recent “Outstanding Results” in MCL Mean for Practice

85

The Quest to Cure CLL: “Remarkable” Results With New Strategy

86

Which Data From the 2023 World Conference on Lung Cancer Are Most Likely to Change Practice?

87

“Really Impactful” New Guidelines for Stage IV NSCLC With Driver Alterations

88

More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists

89

Will HER3 Targeting Change Breast Cancer Care?

90

“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now

91

“Don’t Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast Cancer

92

mRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next?

93

“Major Wins” in Lung Cancer Treatment: How “Explosion of Data” Is Changing Practice

94

“Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?”

95

Pragmatica-Lung Tests a Treatment and a New Approach to Trials

96

The Best First Step in Metastatic NSCLC Care

97

Neo- and Adjuvant Treatments Are Changing Care in Early NSCLC

98

NALIRIFOX Changes Care in Pancreatic Cancer: Here’s How

99

Matching Breast Cancer Patients to Therapies: Here’s How

100

Myelofibrosis Remains Tough to Treat, But New Drugs Are Paving the Way